Forteo ® (teriparatide injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

FORTEO® (teriparatide injection): During and After Pregnancy

Forteo is classified as pregnancy category C. There are no adequate and well controlled studies of Forteo in pregnant or nursing women.



Teriparatide should not be administered to women who are pregnant or nursing. Lilly has not studied the effect of teriparatide treatment on human fetal development or if teriparatide is secreted in breast milk.

Pregnancy During Teriparatide Treatment

Teriparatide should be discontinued when pregnancy is determined. The effect of teriparatide on human fetal development has not been studied and the potential risk for humans is unknown.

Animal Studies

Based on animal studies, use during pregnancy may cause fetal harm.1

Pregnant mice received teriparatide during organogenesis at subcutaneous doses 8 to 267 times the human dose. At doses ≥60 times the human dose, the fetuses showed an increased incidence of skeletal deviations or variations, such as interrupted rib, extra vertebra, or extra rib.1

When pregnant rats received teriparatide during organogenesis at subcutaneous doses 16 to 540 times the human dose, the fetuses showed no abnormal findings.1

Nursing During Teriparatide Treatment

It is not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on the breastfed infant.1

Animal Studies

In a perinatal/postnatal study, pregnant rats received subcutaneous teriparatide from organogenesis through birth of the offspring and continued to receive teriparatide through lactation.1

Pregnant rats that were dosed subcutaneously through lactation experienced

  • mild growth retardation in female offspring at doses ≥120 times the human dose
  • mild growth retardation in male offspring at maternal doses 540 times the human dose, and
  • reduced motor activity in both male and female offspring at maternal doses 540 times the human dose.1

There were no developmental or reproductive effects in mice or rats at doses 8 or 16 times the human dose, respectively.1

Pregnancy After Teriparatide Treatment

Pregnancy outcomes in humans have not been studied after a full course of teriparatide treatment. Lilly has not followed patients after a course of therapy to successful pregnancy to determine an appropriate time frame once off the drug and before becoming pregnant.

Enclosed Prescribing Information


1Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: February 21, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical